22:39 , Jul 9, 2019 |  BC Extra  |  Company News

July 9 Company Quick Takes: Celgene, Nimbus expand deal; plus Gilead-Lyndra, Darzalex and more

Celgene gets option for Nimbus' HPK1 program  Celgene Corp. (NASDAQ:CELG) expanded its partnership with Nimbus Therapeutics LLC (Cambridge, Mass.) to include an option for the latter's HPK1 inhibitor to treat cancer, which Celgene can exercise...
15:20 , May 4, 2018 |  BC Week In Review  |  Clinical News

Altimmune reports Phase IIa data for intranasal influenza vaccine

Altimmune Inc. (NASDAQ:ALT) reported data from a Phase IIa trial in 60 healthy volunteers showing that the two highest doses of its recombinant intranasal influenza vaccine NasoVAX led to 100% seroprotection. The company also said...
15:19 , May 4, 2018 |  BC Week In Review  |  Clinical News

Altimmune evaluating next steps for HBV vaccine

Altimmune Inc. (NASDAQ:ALT) said HepTcell (FP-02.2) given on days one, 29 and 57 as an add-on to entecavir or tenofovir was well tolerated but led to "inconclusive" T cell immunogenicity results in a Phase Ib...
00:42 , Aug 12, 2017 |  BioCentury  |  Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
21:57 , Jan 20, 2017 |  BC Week In Review  |  Company News

PharmAthene, Altimmune deal

PharmAthene and Altimmune will merge into a publicly traded immunotherapeutics company based in Gaithersburg. The newco will retain Altimmune’s name and trade on NYSE MKT under the ticker ALT. Altimmune shareholders will own 58.2% of...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Company News

Altimmune, U.S. Department of Health and Human Services infectious news

HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded Altimmune a five-year contract worth up to $120.2 million to develop its anthrax vaccine candidate NasoShield . Altimmune will receive $14.3 million to fund a Phase...
07:00 , Aug 1, 2016 |  BC Extra  |  Financial News

BARDA awards Altimmune anthrax contract

Altimmune Inc. (Gaithersburg, Md.) said HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded it a contract for up to $120.2 million to fund clinical development of anthrax vaccine candidate NasoShield (formerly AdVAV anthrax vaccine...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

HepTcell: Phase I started

Vaxin began a double-blind, placebo-controlled, dose-escalation, U.K. Phase I trial to evaluate HepTcell in 72 patients with chronic HBV infection. Vaxin Inc. , Rockville, Md.   Product: HepTcell ( FP-02.2 )   Business: Infectious  ...
07:00 , Jul 23, 2015 |  BC Innovations  |  Tools & Techniques

Gene therapy's coming of age

After more than 20 years of trial and error in gene therapy, the field is taking off with one product approved in Europe, several poised to enter the market in the U.S., a surge of...
02:25 , Apr 14, 2015 |  BC Extra  |  Company News

Management tracks

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) hired Ramona Sequeira as president of its U.S. business unit. She succeeds Doug Cole, who stepped down March 31. Sequeira was VP of Lilly USA at Eli Lilly and Co....